FeesSafety
Pluang+

BHAV Acquisition Corp II prices $100M IPO, trading starts on Nasdaq Oct 29, 2026

29 Oct 2026, 03:30 WIB
GlobeNewsWire
View Source
Neutral
BHAV Acquisition Corp II prices $100M IPO, trading starts on Nasdaq Oct 29, 2026

BHAV Acquisition Corp II announced the pricing of its initial public offering (IPO) at $10 per unit, raising $100 million by offering 10 million units. Each unit includes one Class A ordinary share and one right, with the rights convertible into additional shares after a business combination. The units will begin trading on Nasdaq under the ticker 'BHAIU' on October 29, 2026, with shares and rights trading separately under 'BHAI' and 'BHAIR' later. Maxim Group LLC manages the offering, which may include an additional 1.5 million units if over-allotments occur. The IPO proceeds will support BHAV's goal of completing a business combination as a special purpose acquisition company (SPAC).

BHAV Acquisition Corp II's IPO pricing is the focus, here is Pluang's market snapshot for Financials-sector US stocks as of Oct 29, 2026 07:02 WIB: Of 142 priced stocks, 90 rose and 50 fell today. Notable movers include SLDE at USD 27.25 with a 1-day change of -4.02% and a typical hold time on Pluang of 14 days; ITUB at USD 7.38 with a 1-day change of -3.78%, Pluang order activity 100% Sell and 0% Buy, and a typical hold time of 3 days; LU at USD 8.19 with a 1-day change of -3.65%, Pluang order activity 96% Sell and 4% Buy, and a typical hold time of 16 days.

More News

China's coffee market to reach $8.04B by 2032, driven by cafe culture and specialty coffee growth.

China's coffee market to reach $8.04B by 2032, driven by cafe culture and specialty coffee growth.

China's coffee market is projected to grow from $5.8 billion in 2026 to $8.04 billion by 2032, at a CAGR of 5.54%. Growth is fueled by expanding chain cafes, specialty coffee methods like cold brew, and rising homegrown brands. However, rising coffee...

Market News
Neutral
1 hour ago
FDA grants orphan drug status to sovleplenib for rare autoimmune disease ITP treatment

FDA grants orphan drug status to sovleplenib for rare autoimmune disease ITP treatment

HUTCHMED announced that the US FDA has granted orphan drug designation to sovleplenib for treating primary immune thrombocytopenia (ITP), a rare autoimmune disorder causing low platelet counts and bleeding risks. This status provides benefits like 7 ...

Market News
Bullish
1 hour ago
LUXEED hosts global media test drive showcasing advanced tech and luxury in new LLounge and Stormax models.

LUXEED hosts global media test drive showcasing advanced tech and luxury in new LLounge and Stormax models.

LUXEED held a global media test drive event at Chery's International Headquarters in Vu Hồ, featuring the luxury MPV LLounge and the high-performance Stormax SUV. Media representatives and influencers from UAE, Thailand, and Indonesia experienced a 1...

Market News
Bullish
1 hour ago
Law firm investigates NVE Corporation over sharp Q2 revenue drop and stock plunge.

Law firm investigates NVE Corporation over sharp Q2 revenue drop and stock plunge.

Kirby McInerney LLP is investigating NVE Corporation for possible violations of federal securities laws after the company reported a 47% revenue decline and a 33.7% stock price drop following its Q2 fiscal 2027 results. The revenue fall was attribute...

Market News
Bearish
3 hours ago
Fort Technology warned by Nasdaq for falling below $1 minimum bid price, given 180 days to comply.

Fort Technology warned by Nasdaq for falling below $1 minimum bid price, given 180 days to comply.

Fort Technology received a notification from Nasdaq on October 13, 2026, stating it failed to meet the minimum bid price requirement of $1.00 per share over the past 30 days. The company has 180 days, until April 12, 2027, to restore its share price ...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App